Bio-Techne Corp
A maker of the proteins, antibodies, and lab instruments that scientists use to study cells and diagnose disease, Bio-Techne sells brands like R&D Systems and ProteinSimple to researchers worldwide. It began in 1976 in Minneapolis as R&D Systems, making controls to verify blood-analysis machines, and rebranded as Bio-Techne in 2014 — a name blending "bio" with the Greek word "techne," meaning art or craft. Its first product, launched in 1977, was a platelet-rich-plasma control.
Granted 1.29M · Sold 85.4K
Granted 506.3K · Sold 19.8K
Granted 226.1K · Sold 14.7K
Granted 59.3K · Sold 8.1K
Granted 22.7K · Sold 20.1K
Granted 38.3K · Bought 300 · Sold 33.0K
Granted 52.7K · Sold 36.4K
Granted 10.2K · Sold 8.0K
Granted 25.8K
Granted 5.3K
Granted 5.3K
Granted 5.3K
Granted 5.3K
Granted 11.9K
Granted 16.9K
Granted 1.4K
Granted 1.6K
Granted 12.9K · Sold 11.8K
Granted 2.1K
Granted 28.0K · Sold 28.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Kummeth Charles R.Chief Executive Officer, Director · 23 transactions | — | 1.53Mas of Aug 2023 | 1.29M | — | 85.4K |
| Hippel JamesCFO · 36 transactions | +1315.7% | 153.7K | 506.3K | — | 19.8K |
| Kelderman KimChief Executive Officer, Director · 32 transactions | +5207.5% | 89.8K | 226.1K | — | 14.7K |
| Higgins John LDirector · 24 transactions | +790.3% | 66.9K | 59.3K | — | 8.1K |
| Furlow Brenda S.SVP - GENERAL COUNSEL · 18 transactions | — | 52.0Kas of Dec 2022 | 22.7K | — | 20.1K |
| Baumgartner Robert VDirector · 10 transactions | +241.6% | 46.5K | 38.3K | 300 | 33.0K |
| Nusse RoelandDirector · 11 transactions | +313.9% | 44.6Kas of Aug 2025 | 52.7K | — | 36.4K |
| Steer Randolph CDirector · 8 transactions | +180.7% | 24.2Kas of Oct 2023 | 10.2K | — | 8.0K |
| Geist WilliamPRESIDENT, PROTEIN SCIENCES · 9 transactions | — | 20.5K | 25.8K | — | — |
| Keegan Joseph DDirector · 5 transactions | +620.5% | 15.4K | 5.3K | — | — |
| Seth AlpnaDirector · 5 transactions | +115.2% | 15.4K | 5.3K | — | — |
| Vessey RupertDirector · 5 transactions | +963.6% | 11.0K | 5.3K | — | — |
| Bushman Julie LDirector · 5 transactions | +1728.1% | 8.8K | 5.3K | — | — |
| McManus MatthewPresident - Diag & Spatial Bio · 6 transactions | — | 7.7K | 11.9K | — | — |
| Bohnen ShaneSVP - General Counsel · 12 transactions | — | 7.2K | 16.9K | — | — |
| Crouse Steven C.President - Diag & Spatial Bi · 4 transactions | — | 6.8K | 1.4K | — | — |
| Klimovsky Judith V.Director · 1 transaction | — | 3.8K | 1.6K | — | — |
| Herr Amy E.Director · 13 transactions | — | 2.9K | 12.9K | — | 11.8K |
| Klimovsky Judith VDirector · 2 transactions | — | 2.1Kas of Oct 2024 | 2.1K | — | — |
| Eansor Norman DavidPresident-Protein Sciences · 13 transactions | -25.9% | 2.1Kas of Nov 2021 | 28.0K | — | 28.7K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -265.7K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.